In the first reporting period, the project's objectives focused on efficient management, coordination, and technical progress. Technically, user requirements were collected, and the RETENTION platform's architecture was developed iteratively with cross collaboration among clinical and technical partners. A data model was defined using widely used ontologies to develop data repositories and transmission mechanisms. Medical devices and sensors were tested and selected, Patient Edge devices were integrated and the mobile application was created. The CSB Dashboard was integrated with the Security Component, ML training workflows, and the DSS, using a micro-services architecture and continuous integration. The platform was tested and fine-tuned in a virtual Pilot of Pilots (vPoP) process.
In the second reporting period, significant technical advancements included the completion of the integrated RETENTION platform, with the mobile app supporting multiple health devices. The CSB Dashboard saw major improvements, and new DSS functionalities were added. The Security Component and data repositories were updated, and the ML Tool was redeployed. Extensive testing ensured system reliability, with dockerised containers enabling distinct platform instances for each hospital. Preparation for the RCT commencement progressed well with device acquisition and patient recruitment. The first patients were enrolled at the end of this period.
In the third reporting period, the project mainly focused on the RCT conduct. From a technical perspective, a distinct instance of the platform was deployed for each hospital on the same virtual machine using dockerised containers and a reverse proxy. From the moment the clinical trial started, on 24 April 2024, a problem reporting mechanism was established to report any technical issue encountered. The scope of this mechanism extended beyond initial problem reporting, to also cover for platform improvements and additional features requested by the clinicians. From a clinical perspective, each clinical team focused on the Trial conduct in their own hospital, involving patient recruitment, enrolment and training, setting-up the set of home devices, assuring ethics compliance, implementing the procedures for the proper implementation of the clinical protocol and patients’ follow-up. At the end of this period, the patient recruitment phase concluded with a total of 390 patients enrolled, comprising 219 HF, 64 LVAD and 107 HTx. Although slightly below the original total target of 450 patients by a percentage of 13.3%, the final sample size is supported by the revised statistical power analysis and remains adequate to assess the study’s primary objectives. Project assessment regarding the Ethical use of AI has been introduced in this reporting period, to ensure adherence to the EU framework for ethical development and use of AI. A phased implementation of the European Commission’s Assessment List for Trustworthy AI (ALTAI) was designed and executed.
Alongside technical and clinical work, the horizontal activities of project management, dissemination, communication, standardisation, sustainability and ethics monitoring are being performed in line with the Description of the Action (DoA) and the evolving project environment throughout all project phases.